KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBT Margin (2016 - 2025)

Neogenomics' EBT Margin history spans 16 years, with the latest figure at 6.52% for Q4 2025.

  • For Q4 2025, EBT Margin rose 285.0% year-over-year to 6.52%; the TTM value through Dec 2025 reached 15.16%, down 295.0%, while the annual FY2025 figure was 15.16%, 295.0% down from the prior year.
  • EBT Margin reached 6.52% in Q4 2025 per NEO's latest filing, up from 14.05% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 60.33% in Q2 2021 to a low of 45.37% in Q1 2022.
  • Average EBT Margin over 5 years is 15.83%, with a median of 17.92% recorded in 2023.
  • Peak YoY movement for EBT Margin: surged 8097bps in 2021, then plummeted -9314bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 35.16% in 2021, then skyrocketed by 48bps to 18.4% in 2022, then soared by 47bps to 9.83% in 2023, then grew by 5bps to 9.38% in 2024, then surged by 30bps to 6.52% in 2025.
  • Per Business Quant, the three most recent readings for NEO's EBT Margin are 6.52% (Q4 2025), 14.05% (Q3 2025), and 25.27% (Q2 2025).